Teva launches Lovenox and Zyvox generics in USA; in deal with Eagle

Israeli generic giant Teva Pharmaceutical Industries (NYSE: TEVA) has launched a generic equivalent of French pharma major Sanofi’s (Euronext: SAN) Lovenox (enoxaparin sodium injection) in seven dosage strengths in the USA.

The drug is used for prophylaxis of deep vein thrombosis (DVT) in patients undergoing abdominal surgery, hip or knee replacement surgery, or in medical patients with severely restricted mobility during acute illness; and also for the treatment of acute DVT. Lovenox had annual sales of around $1.8 billion in the USA, according to IMS data as of November 2014 quoted by Teva. Under a licensing agreement, Teva has partnered with Chemi SPA to leverage its internal research based technologyin the development and manufacture of Enoxaparin Sodium Injection, USP.

Teva has also recently launched the generic equivalent to US pharma giant Pfizer’s (NYSE: PFE) Zyvox (linezolid) Injection which is used for the treatment of infections caused by Gram-positive bacteria. Zyvox Injection had annual sales of about $464 million in the USA, according to IMS data as of October 2014.